Mr. Soni has 26 years experience in a broad range of environmental engineering and strategic consulting for industry, the majority of which has been to the pharmaceutical sector. He is widely recognized for his technical and regulatory knowledge in the environmental field, and for guiding clients through environmental compliance in a manner which meets the clients’ business objectives. He is the President and founder of IES. He holds a BS in Chemical Engineering, an MS in Water Resources Engineering, and is a registered Professional Engineer.

Mr. Schellin is an entrepreneurially minded C-level executive and business strategist diagnosing and building alignment around market opportunities and taking organizations from challenges to thriving enterprises. Mr. Schellin excels at turning businesses and teams around; creating a vision of the future, bringing people together around the mission and inspiring engagement and action to achieve goals. He has over 25 years of experience in the Life Sciences Industry, ranging from startup to international multi-site responsibility across the drug product, drug substance, and medical device sectors. Mr. Schellin has held senior executive level positions with operating leadership roles, focusing on M&A evaluations, pre- and post-integration strategy, execution of integration plans, along with buy side and sell side advisory. He successfully developed a specialty sterile and drug delivery CDMO business in Irvine, California, subsequently selling it to Siegfried. Prior to entering the consulting field, Mr. Schellin was Siegfried’s SVP, Global Head of Drug Product Operations and US Drug Substance. Today, Mr. Schellin provides consulting services to the Life Science Industry, where he specializes in operational performance, interim management, site evaluations, mergers, acquisitions, and post integration support. He focuses on assisting companies with strategic decisions, and business operations advisory. Mr. Schellin holds a bachelor’s degree in Political Science and Business Administration from DePaul University.

Mr. Braithwaite was President and CEO of Accupac (retired), a leading contract manufacturing company serving the Pharmaceutical Industry. Currently, Mr. Braithwaite is the President of PharmaSource Consulting, Inc., a consulting company serving the Pharmaceutical Industry. Mr. Braithwaite is an active member of PharmaBioSource’s Industry Advisory Board.

Mr. Tarantino is a licensed broker with more than 40 years of experience in the Real Estate Industry. He has held many official positions in the real estate industry including member of the Pennsylvania State Real Estate Commission. Mr. Tarantino is also consultant to several banking organizations as well as the Montgomery County (PA) Commissioners and the Pennsylvania Turnpike Commission.

Ms. O’Neill has three years of experience within the non-profit industry and five years of progressive experience within the financial services industry, specializing in software application testing. She has been responsible for leading a team of software application testers and mentoring team members by teaching and coaching throughout project life cycle and final release. Ms. O’Neill also has a Bachelor of Science degree in Elementary Education.

Ms. Divaker has over 20 years of experience in various fields including reporting, accounting, marketing and office management.  She also has international experience in project management.  Ms. Divaker graduated from Osmania University, India with a B.A. in Accounting.

Ms. Morales has more than 15 years of experience in the areas of pharmaceutical technology, quality assurance, and regulatory compliance while maintaining ties with academia via a part-time Visiting Professor appointment at the UPR School of Pharmacy Industrial Pharmacy Program.

Dr. Hensler is a Biochemical Engineer with 18 years of international cGMP pharmaceutical manufacturing, quality assurance and engineering experience, with particular emphasis on production of bulk biopharmaceuticals including cytokines, monoclonal antibodies, vaccines and blood products. He has extensive knowledge of manufacturing compliance, validation and regulatory requirements for bulk biopharmaceutical facilities according to US FDA, EMEA and ICH regulations (API’s and final dosage forms). Dr. Hensler is technically proficient on many aspects of biopharmaceutical processing, with emphasis on large scale bulk production and process validation.

Mr. Ventura has over 25 years experience in executive management and technical operations in the pharmaceutical industry. He has proven leadership in product and process development, process validation, general plant management, facility construction, commissioning and start-up.  Extensive technical operations experience with knowledge in manufacturing excellence, Quality by Design/PAT, QA/QC, regulatory/compliance, technology development and transfer, and training. Broad exposure to all aspects of pharmaceutical supply chain management in solid, liquid, and sterile dosage products with extensive lyophilization experience.

Mr. Zeitz has 30 years of experience in the pharmaceutical industry with various levels of increasing responsibilities in business development, 3rd party sales and contract manufacturing of API and finished dosage forms.  He held these positions at Huemann Pharma, Pharmacia, Pfizer and Fareva.  Mr. Zeitz has a Master of Science degree in Economics from the University of Frankfurt / Main.

Mr. Accettura has 30 years of BioPharma industry experience with both Big Pharma – Pfizer, Roche, BMS as well as Emergent and Virtual Pharma companies – Anesta/Cephalon, RxKinetix, Kyowa Pharmaceuticals, Dainippon Sumitomo Pharma America/Sunovion, and Braeburn Pharmaceuticals. He has held executive level positions in the areas of supply chain, new product development and technical operations. Mr. Accettura has overseen the development of end-to-end global supply chain strategies and commercial readiness roadmaps for major branded product launches across the US, Europe and Asia. He earned a B.S. with distinction from Cornell University in Mechanical Engineering and also holds a M.S. from University of Illinois and a MBA from the Stern School at New York University.

Mr. Zicot is an engineer with a broad range of international experience in the technical aspects of pharmaceutical manufacturing processes – engineering / commissioning / maintenance / optimization / validation. His technical knowledge in the area of production includes: powder processes, IBC’s technology, packaging equipment (blisters, bottles, sachets), powder and liquid (aseptic) filling, handling systems, tableting machines, coating, capsuling machines, onguent, blending, granulation, drying (fluid bed dryer, spray dryer, freeze dryer) compaction, sterilization (autoclaves, UV, tunnel), solvent storage, explosion proof (EEX) area, centrifugal dryers, primary chemical plant.

Ms. Schwiegerath is a chemist with more than 20 years of experience in Pharmaceutical R&D analytical research. She has expertise in Analytical Research, method development, method validation, stability testing, raw materials testing and technology transfer to manufacturing. She is also experienced in preparation and editing of IND and NDA submissions to FDA.

Ms. Mukherji has 20 years of experience in consulting experience involving the delivery of strategies and solutions for regulatory compliance in the FDA and EMEA regulated pharmaceutical, biotech and medical device industries.  Her expertise includes leading teams to develop and deliver QA and regulatory strategies and solutions for GMP compliance as well as numerous due diligence exercises.  Before joining PharmaBioSource, Ms. Mukherji worked at Clarkston Consulting and KMI, a division of Parexel.  She holds a B.S. in Biochemistry from the University of Rochester.

Mr. Crawford has a B.A. in Business Administration from Pennsylvania State University.  He has experience in pharmaceutical and biotech market research and analysis.